Ironwood Pharmaceuticals
IRWD
239 hedge funds and large institutions have $2.02B invested in Ironwood Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 76 increasing their positions, 78 reducing their positions, and 31 closing their positions.
279% more call options, than puts
Call options by funds: $876K | Put options by funds: $231K
81% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 31
9.13% more ownership
Funds ownership: 104.64% → 113.77% (+9.1%)
8% more funds holding
Funds holding: 221 → 239 (+18)
3% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 78
3% less capital invested
Capital invested by funds: $2.09B → $2.02B (-$72.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$146M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$32.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$30.5M |
| 4 |
Renaissance Technologies
New York
|
+$27M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
-$73.3M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$30.5M |
| 3 |
Goldman Sachs
New York
|
-$19.2M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$19M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.5M |
IRWD Hedge Fund Activity: Q2 2022 in Review
239 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q2 2022, worth a combined $2.02B — down 3.5% from $2.09B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new IRWD positions and 31 closed out — a net gain of 25 holders — while 76 added to existing stakes and 78 trimmed.
The largest buyer was BlackRock, adding an estimated $146M. The largest seller was Westfield Capital Management, cutting an estimated $73.3M.
- 239 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q2 2022, up from 221 in Q1 2022.
- Funds reported $2.02B of Ironwood Pharmaceuticals stock for Q2 2022, down 3.5% quarter-over-quarter.
- 56 funds opened new Ironwood Pharmaceuticals positions in Q2 2022 and 31 closed out, a net change of +25 holders.
- The largest Ironwood Pharmaceuticals buyer in Q2 2022 was BlackRock, an estimated $146M added.
- The largest Ironwood Pharmaceuticals seller in Q2 2022 was Westfield Capital Management, an estimated $73.3M sold.
Based on aggregated 13F filings for Q2 2022.